PEAR THERAPEUTICS ANNOUNCES PROGRAM TO BRING PRESCRIPTION DIGITAL THERAPEUTICS TO PATIENTS IN RECOVERY THROUGH A TELEHEALTH PROVIDER EXPERIENCE
- Pear is working with select telehealth providers to put recovery in the hands of those seeking help remotely
- Pear’s first telehealth offering is with PursueCare, a leading telehealth addiction treatment provider, to offer patients an end-to-end virtual continuum of comprehensive addiction recovery care
- Pear intends to announce other telehealth providers joining this initiative
BOSTON–(BUSINESS WIRE)–Apr. 4, 2022– Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options. Pear intends to work with select telehealth providers to help connect patients with a clinician in their state to talk about treatment options, including Pear’s FDA-authorized PDTs reSET® and reSET-O®. Pear’s first telehealth offering included in this program is with PursueCare, a leading telehealth addiction treatment provider with a digital health model for SUD and OUD treatment.
The US has seen an unprecedented increase in drug use and overdose deaths during the COVID-19 pandemic, exacerbated by challenges for people living in isolation or with few viable treatment resources available. Remote and digital care solutions can help to combat these issues and unlike traditional in-person care and medication, telehealth and PDTs can collect real-world data for use by prescribing clinicians and for population health management by payors and health systems.
By working with telehealth providers, Pear can provide an integrated virtual treatment continuum to give patients access to learn about its 24/7 evidence-based therapeutic that can complement their remote outpatient medical treatment and therapy. PursueCare’s virtual care platform and programs deliver Medication-Assisted Treatment (MAT), counseling, psychiatry, delivery pharmacy, at-home screenings, and targeted case management through a simple-to-use app. Pear’s offering with PursueCare has already launched in select markets across PursueCare’s 12-state footprint with expansion to additional states planned.
“We find patients are often required to piece together their treatment like a puzzle. By bringing together and standardizing delivery of comprehensive at-home and digital care solutions, we put the patient at the center and bring them the resources and proven remote behavioral interventions they need, along with treatment from skilled clinicians who can help them navigate their journey,” said Nick Mercadante, PursueCare’s Founder and CEO. “I believe this approach truly drives value-based care and is too often lacking for people who have a substance use disorder and are seeking access to recovery treatment.”
“About only one in 10 Americans with a substance use disorder receives any type of specialty treatment. Barriers to care can include not having access to in-person therapy or long waiting periods to engage care. The power of Pear working with telehealth providers like PursueCare is meeting patients where they are,” said Corey McCann, M.D., Ph.D., Pear’s President and CEO. “We need to make it easier for patients with addiction to seek and learn about treatment options for recovery. By providing innovative, fully virtual evidence-based care and treatment, we can create equity of access, and remove many of the obstacles associated with treatment.”
About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.
Important Safety Information from Pear Therapeutics about reSET
Indications for Use:
reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.
It is intended to:
- increase abstinence from a patient’s substances of abuse during treatment, and
- increase retention in the outpatient treatment program.
Important Safety Information for Clinicians:
Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).
Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.
reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.
The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.
The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.
This Press Release does not include all the information needed to use reSET safely and effectively. Please see the Clinician Brief Summary for reSET for more information.
Important Safety Information from Pear Therapeutics about reSET-O
Indications for Use
reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only prescription digital therapeutic.
Important Safety Information:
Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications). Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.
reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.
Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.
The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.
This Press Release does not include all the information needed to use reSET-O safely and effectively. Please see the Clinician Brief Summary Instructions for reSET-O for more information.
Forward-Looking Statements from Pear Therapeutics
Certain statements and projections in this press release may be considered forward-looking statements within the meaning of the federal securities laws. Forward looking statements generally relate to future events or involving, or future performance of, Pear. For example, statements regarding anticipated access to Pear’s products are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “aim”, “estimate”, “anticipate”, “believe”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Pear and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) delay or reluctance by patients and/or providers to adopt, request or use Pear’s products, (ii) whether Pear’s initiative in telehealth with PursueCare or other telehealth providers will be successful, (iii) whether telehealth solutions drive value-based care; (iv) the possibility that Pear may be adversely affected by other economic, business, regulatory, and/or competitive factors; (v) the evolution of the markets in which Pear competes; (vi) the impact of the COVID-19 pandemic on Pear’s business; (vi) changes in applicable laws or regulations; and (viii) other risks and uncertainties set forth in Pear’s future filings with the SEC. These filings will identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and Pear assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Pear gives no assurance that Pear will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by Pear or any other person that the events or circumstances described in such statement are material.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005347/en/
Media and Investors
Senior Director, Corporate Communications
Source: Pear Therapeutics, Inc.Back